Market Overview

Celgene Says ABRAXANE Demonstrates Statistically Significant Improvement

Related CELG
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Stock Market News for April 14, 2014 - Market News

Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE^® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone.

Posted-In: News FDA

 

Most Popular

Related Articles (CELG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free